Commentary to "Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials" (Galvano et al. J Bone Oncol 2019; 18:100252).
Fiche du document
- doi: 10.1016/j.jbo.2020.100294
- issn: 2212-1366
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jbo.2020.100294
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32742916
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2212-1366
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_4DEC0E9E3BD04
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
State trials Prostate gland Glandula prostata Prostata Gland, Prostate Hormones--Therapeutic use Endocrine therapy Wellness Personal health Cancer survivors Survivors, Cancer Cancer patients Breasts Biography--HealthCiter ce document
E. Gonzalez-Rodriguez et al., « Commentary to "Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials" (Galvano et al. J Bone Oncol 2019; 18:100252). », Serveur académique Lausannois, ID : 10.1016/j.jbo.2020.100294
